Julie Hambleton

4.0k total citations · 4 hit papers
31 papers, 3.0k citations indexed

About

Julie Hambleton is a scholar working on Hematology, Cardiology and Cardiovascular Medicine and Internal Medicine. According to data from OpenAlex, Julie Hambleton has authored 31 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 9 papers in Cardiology and Cardiovascular Medicine and 8 papers in Internal Medicine. Recurrent topics in Julie Hambleton's work include Venous Thromboembolism Diagnosis and Management (8 papers), Atrial Fibrillation Management and Outcomes (6 papers) and Blood Coagulation and Thrombosis Mechanisms (6 papers). Julie Hambleton is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (8 papers), Atrial Fibrillation Management and Outcomes (6 papers) and Blood Coagulation and Thrombosis Mechanisms (6 papers). Julie Hambleton collaborates with scholars based in United States, Canada and United Kingdom. Julie Hambleton's co-authors include Fairooz F. Kabbinavar, Herbert I. Hurwitz, Somnath Sarkar, R. Mass, Emily K. Bergsland, Louis Fehrenbacher, W. Heim, John D. Hainsworth, Eric Holmgren and Jordan Berlin and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Julie Hambleton

31 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer

2007 574 citations Julie Hambleton et al. profile →
Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer

2005 550 citations Julie Hambleton et al. profile →
Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism

2003 544 citations Clive Kearon, Jeffrey S. Ginsberg et al. New England Journal of Medicine profile →
Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer

2005 522 citations Julie Hambleton et al. profile →

Peers

Julie Hambleton

ONCOL

CCM

PRM

SURGE

Shenhong Wu United States

Rodolfo Passalacqua Italy

Xiaolei Zhu China

Sergio Ricci Italy

D C Tormey United States

H.J. Keizer Netherlands

Nathan Levitan United States

V. Bramwell Canada

Fabio A.B. Schutz United States

Chris E. Holmes United States

Shenhong Wu United States

Julie Hambleton

2.9k ×2.6

ONCOL

289 ×0.4

842 ×1.3

CCM

1.7k ×2.8

PRM

424 ×0.7

SURGE

Citations per year, relative to Julie Hambleton Julie Hambleton (= 1×) peers Shenhong Wu

Countries citing papers authored by Julie Hambleton

Since Specialization

Citations

This map shows the geographic impact of Julie Hambleton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Hambleton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Hambleton more than expected).

Fields of papers citing papers by Julie Hambleton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Hambleton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Hambleton. The network helps show where Julie Hambleton may publish in the future.

Co-authorship network of co-authors of Julie Hambleton

This figure shows the co-authorship network connecting the top 25 collaborators of Julie Hambleton. A scholar is included among the top collaborators of Julie Hambleton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Hambleton. Julie Hambleton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

O’Brien, Carol, et al.. (2020). Abstract 4152: Preclinical evaluation of PRKC fusions and GNA11/GNAQ mutations as genetic drivers of PKC activation in non-MUM indications to support a phase 1/2 basket trial of IDE196. Cancer Research. 80(16_Supplement). 4152–4152. 1 indexed citations

Brahmer, Julie R., Drew Rasco, Minjia Chen, et al.. (2016). Abstract B143: A phase 1a/1b study of FPA008 in combination with nivolumab in patients with selected advanced cancers. Cancer Immunology Research. 4(1_Supplement). B143–B143. 9 indexed citations

Sandler, Alan, Jing Yi, Suzanne E. Dahlberg, et al.. (2010). Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(9). 1416–1423. 125 indexed citations

Denlinger, Crystal S., Rebecca Blanchard, Lu Xu, et al.. (2009). Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 65(1). 97–105. 21 indexed citations

Kearon, Clive, Jim A. Julian, Michael J. Kovacs, et al.. (2008). Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood. 112(12). 4432–4436. 81 indexed citations

Rios, Jorge A., Julie Hambleton, Maurene Viele, et al.. (2006). Viability of red cells prepared with S‐303 pathogen inactivation treatment. Transfusion. 46(10). 1778–1786. 22 indexed citations

Alarcón, Pedro A. de, Richard J. Benjamin, Marion Dugdale, et al.. (2005). Fresh frozen plasma prepared with amotosalen HCl (S‐59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion. 45(8). 1362–1372. 58 indexed citations

Stratmann, Greg, Elaine Tseng, Julie Hambleton, et al.. (2004). Reversal of Direct Thrombin Inhibition After Cardiopulmonary Bypass in a Patient with Heparin-Induced Thrombocytopenia. Anesthesia & Analgesia. 98(6). 1635–1639. 57 indexed citations

Auerbach, Andrew D., Gillian D Sanders, & Julie Hambleton. (2004). Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis. The American Journal of Medicine. 116(12). 816–828. 30 indexed citations

10.

Kearon, Clive, Jeffrey S. Ginsberg, Michael J. Kovacs, et al.. (2003). Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism. New England Journal of Medicine. 349(7). 631–639. 544 indexed citations breakdown →

11.

Hambleton, Julie. (2003). Home Monitoring of Anticoagulation. Journal of Thrombosis and Thrombolysis. 16(1-2). 39–42. 13 indexed citations

12.

Lal, Geeta, Todd V. Brennan, Julie Hambleton, & Orlo H. Clark. (2003). Coagulopathy, Marantic Endocarditis, and Cerebrovascular Accidents as Paraneoplastic Features in Medullary Thyroid Cancer—Case Report and Review of the Literature. Thyroid. 13(6). 601–605. 15 indexed citations

13.

Hambleton, Julie, David Wages, Melanie Adams, et al.. (2002). Pharmacokinetic study of FFP photochemically treated with amotosalen (S‐59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion. 42(10). 1302–1307. 54 indexed citations

14.

Norian, J.M., et al.. (2002). Total Knee Arthroplasty in Hemophilic Arthropathy. Journal of Bone and Joint Surgery. 84(7). 1138–1141. 86 indexed citations

15.

Hambleton, Julie, Lawrence Leung, & Marcel Levi. (2002). Coagulation: Consultative Hemostasis. Hematology. 2002(1). 335–352. 40 indexed citations

16.

Chang, Thomas J., et al.. (2001). Hemophilic Arthropathy: Considerations in Management. Journal of the American Podiatric Medical Association. 91(8). 406–414. 9 indexed citations

17.

Hambleton, Julie. (2001). Advances in the treatment of von Willebrand disease. Seminars in Hematology. 38(4 Suppl 9). 7–10. 4 indexed citations

18.

Hambleton, Julie. (2001). Diagnosis and incidence of inherited von Willebrand disease. Current Opinion in Hematology. 8(5). 306–311. 10 indexed citations

19.

Kuschner, Ware G., Alessandra D’Alessandro, Julie Hambleton, & Paul D. Blanc. (1998). Tumor Necrosis Factor-Alpha and Interleukin-8 Release From U937 Human Mononuclear Cells Exposed to Zinc Oxide In Vitro. Journal of Occupational and Environmental Medicine. 40(5). 454–459. 11 indexed citations

20.

Wages, David, Ilona Staprãns, Julie Hambleton, Nathan M. Bass, & Laurence Corash. (1998). Structural characterization and functional effects of a circulating heparan sulfate in a patient with hepatocellular carcinoma. American Journal of Hematology. 58(4). 285–292. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact